The Centers for Disease Control (CDC) has approved a new shot called ‘nirsevimab’ to prevent respiratory syncytial virus (RSV) in infants under 8 months, marking a significant advancement in combating the most common cause of bronchiolitis and pneumonia in young children in the U.S.
Unlike an immunization that triggers the body to produce antibodies, this treatment is an injection of antibodies.
Designed to last for five to six months, it can effectively cover children throughout the cold season.
Doctors call the shot as a “huge breakthrough,” estimating its cost at $500 per shot but emphasizing its cost-effectiveness compared to hospital treatment for RSV.
FingerLakes1.com is the region’s leading all-digital news publication. The company was founded in 1998 and has been keeping residents informed for more than two decades. Have a lead? Send it to [email protected].